Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,227.43
    +55.28 (+0.68%)
     

  • Bitcoin USD

    61,582.12
    +3,243.08 (+5.56%)
     

  • CMC Crypto 200

    1,325.95
    +48.97 (+3.84%)
     

  • S&P 500

    5,112.55
    +48.35 (+0.95%)
     

  • Dow

    38,633.14
    +407.48 (+1.07%)
     

  • Nasdaq

    16,104.16
    +263.20 (+1.66%)
     

  • Gold

    2,304.10
    -5.50 (-0.24%)
     

  • Crude Oil

    78.63
    -0.32 (-0.41%)
     

  • 10-Yr Bond

    4.5020
    -0.0690 (-1.51%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Pacira BioSciences
·1-min read
Pacira BioSciences
Pacira BioSciences

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.


CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com